Moderna Inc. ($MRNA) Stock Forecast: Down 5.2% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its innovative mRNA technology, notably showcased during the COVID-19 pandemic through its vaccine development.

Why is Moderna Inc. going down?

MRNA stock is down 5.2% on Feb 20, 2025 15:11

• Moderna (MRNA) revealed Q4 earnings that fell short of EPS predictions and displayed a decrease in revenue, prompting a downward trend in the market.
• The FDA's decision to pause Moderna's norovirus vaccine trial following a Guillain-Barré syndrome case possibly raised apprehensions among investors, impacting the stock negatively.
• Analysts expressing reservations and issuing downgrades on MRNA stock subsequent to the earnings report might have added to the bearish outlook.
• Despite surpassing revenue projections and confirming guidance, the drop in COVID vaccine sales could have also influenced the stock's decline.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News

MRNA and GILD are in the spotlight this week on fourth-quarter earnings release and regulatory update, respectively.

https://www.zacks.com/stock/news/2417908/biotech-stock-roundup-mrnas-q4-results-gilds-update-other-news

Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges - Moderna ( NASDAQ:MRNA )

Moderna posted a Q4 EPS loss of $ ( 2.91 ) , missing estimates, while revenue fell to $966M from $2.81B but beat the $942.8M consensus Moderna's norovirus vaccine trial is on FDA hold due to a Guillain-Barré syndrome case but expects no impact on efficacy readout timing.

https://www.benzinga.com/25/02/43793190/analyst-has-confidence-in-modernas-cancer-vaccine-but-highlights-declining-covid-demand-slow-rsv-uptake-challenge

Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release?

Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA stock.

https://www.zacks.com/stock/news/2417378/should-you-buy-hold-or-sell-moderna-stock-post-q4-earnings-release

This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Hims & Hers Health ( NYSE:HIMS ) , Datadog ( NASDAQ:DDOG )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Morgan Stanley analyst Craig Hettenbach downgraded the rating for Hims & Hers Health, Inc.

https://www.benzinga.com/25/02/43781328/this-moderna-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-tuesday

Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.

https://www.zacks.com/stock/news/2416390/moderna-q4-earnings-and-revenues-beat-covid-vaccine-sales-decline

Trending Today

Ethena ($ENA) Crypto Forecast: Down 6.0% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Down 8.7% Today

Memecoin ($MEME) Crypto Forecast: Up 7.7% Today

Maker ($MKR) Crypto Forecast: Up 6.0% Today

Movement ($MOVE) Crypto Forecast: Up 5.1% Today

MANTRA ($OM) Crypto Forecast: Up 5.3% Today

Ethereum ($ETH) Crypto Forecast: Up 5.0% Today

Toncoin ($TON) Crypto Forecast: Up 5.0% Today

Pepe ($PEPE) Crypto Forecast: Up 6.4% Today

dogwifhat ($WIF) Crypto Forecast: Up 9.8% Today

Moderna Inc. Price History

30.00.2025 - MRNA Stock was down 6.2%

• A recent revision of Moderna's stock by an analyst led to a bearish movement, with a lower price target and a shift from Buy to Neutral.
• Despite market fluctuations, Moderna saw a slight increase in its stock, closing at $41.66, showing some resilience.
• Observations on the options activity for Moderna revealed a mixture of bullish and bearish trades, with significant bullish moves from financial giants reflecting varied sentiments among traders.
• Market volatility, possibly influenced by global health concerns such as the CDC-WHO split and the discovery of a rare bird flu strain, may have impacted Moderna's stock performance.

04.01.2025 - MRNA Stock was down 6.8%

• Moderna's stock experienced a bearish trend today following an analyst's decision to downgrade the stock from Buy to Neutral and lower the price target. This downgrade, alongside reduced revenue expectations, likely impacted investor confidence negatively.
• While some investors showed bullish sentiment through options trading, overall market sentiment appears to have been influenced by the pessimistic outlook presented by the analyst.
• Noteworthy options trading activity, encompassing both bullish and bearish trades, suggests uncertainty and volatility surrounding Moderna's stock, potentially contributing to its decline.
• Investor wariness regarding Moderna's future earnings, particularly in anticipation of the forthcoming quarterly results, is evident. This caution aligns with discussions on biotech stocks poised to surpass Q4 earnings estimates.

20.01.2025 - MRNA Stock was down 5.2%

• Moderna (MRNA) revealed Q4 earnings that fell short of EPS predictions and displayed a decrease in revenue, prompting a downward trend in the market.
• The FDA's decision to pause Moderna's norovirus vaccine trial following a Guillain-Barré syndrome case possibly raised apprehensions among investors, impacting the stock negatively.
• Analysts expressing reservations and issuing downgrades on MRNA stock subsequent to the earnings report might have added to the bearish outlook.
• Despite surpassing revenue projections and confirming guidance, the drop in COVID vaccine sales could have also influenced the stock's decline.

28.00.2025 - MRNA Stock was up 5.1%

• Moderna's upward movement today may be linked to securing a significant multi-year contract to supply its COVID-19 vaccine to 17 European countries, potentially boosting its revenue streams and global presence.
• Positive market sentiment could also be influenced by recent statements made by Oracle Chairman Larry Ellison regarding the role of artificial intelligence in revolutionizing cancer treatment, indirectly benefiting Moderna's biotech innovations.
• Ongoing global health issues, such as the CDC-WHO split and the identification of a rare bird flu strain, might have emphasized the importance of vaccine research, highlighting Moderna's competitive position within the industry.
• In conclusion, a series of positive developments related to Moderna's vaccine agreements, technological progress, and the overall healthcare landscape likely contributed to the stock's upward trend.

03.01.2025 - MRNA Stock was down 5.1%

• Despite the general optimism towards Moderna, a recent downgrade from a prominent analyst at Goldman Sachs from Buy to Neutral, accompanied by a lower price target, led to a downward trend in the stock.
• The bullish outlook from investors in options trading did not seem to outweigh the impact of the analyst's downgrade.
• The contrast between the positive options activity and the analyst's downgrade potentially created uncertainty among investors, contributing to the decline in Moderna's stock price.

29.00.2025 - MRNA Stock was down 5.3%

• Moderna's stock faced a downturn post a revision by an analyst at Goldman Sachs, who adjusted the rating from Buy to Neutral and significantly lowered the price target.
• The rationale behind the downgrade was tied to anticipated product revenue falling at the lower end of guidance, sparking worries among investors about upcoming financial performance.
• Despite market challenges, Moderna's stock concluded with a slight uptick, demonstrating resilience amidst negative sentiment stemming from the analyst's actions.
• This occurrence underscores the sway that analyst evaluations and revenue projections hold over stock movements, particularly in the volatile biotech sphere where investor outlook can swiftly change based on perceived growth opportunities.

29.00.2025 - MRNA Stock was up 5.2%

• The upswing in Moderna's stock price might be connected to the acquisition of a multi-year contract to provide its COVID-19 vaccine to 17 European nations. This development marks a significant achievement for the company, signaling a promising revenue outlook.
• The market's favorable response could also be influenced by ongoing global health concerns, including the CDC's suspension of collaboration with the WHO and the detection of a rare bird flu strain in California. This underscores the ongoing necessity for effective vaccines.
• Despite a slight market decline, Moderna's strength and upward trajectory indicate investor faith in the company's adeptness at navigating challenges and seizing opportunities in the healthcare industry.

14.01.2025 - MRNA Stock was up 6.6%

• The company reported a Q4 loss but exceeded revenue estimates, indicating strong financial performance.
• Struggles with scaling down manufacturing and launching new products may have impacted its profitability.
• Investors may be optimistic about the company's future prospects, especially with the potential of its bird flu vaccine candidates and ongoing COVID-19 vaccine sales.
• The bullish movement in the company's stock could be a result of investors focusing on the positive revenue surprise and the long-term growth potential of its vaccine portfolio.

14.01.2025 - MRNA Stock was up 7.1%

• Moderna reported a mixed earnings result, surpassing revenue expectations while recording a larger loss than expected, which potentially caused initial uncertainty in the market.
• The bullish movement in Moderna's stock is possibly due to the market's focus on the company's initiatives to optimize manufacturing processes and introduce new products, showcasing resilience and adaptability within a challenging environment.
• Despite some investors taking a bearish stance in the options market initially, the overall positive sentiment regarding Moderna's future prospects and product pipeline likely eclipsed these short-term bearish signals.
• Investors seem hopeful about Moderna's long-term outlook, particularly with ongoing advancements in vaccine technology, and the company's demonstrated ability to navigate through changing market conditions, contributing to the positive stock movement.

11.01.2025 - MRNA Stock was down 5.3%

• Moderna (MRNA) experienced a bearish movement possibly due to profit-taking after recent surges in its stock price.
• Despite expectations of beating earnings estimates, investors may have been cautious about the company's pipeline updates.
• The focus on other biotech stocks reporting earnings this week may have shifted attention away from Moderna, leading to the bearish movement.
• The overall market sentiment towards biotech stocks and the anticipation of earnings reports could have influenced Moderna's stock performance negatively today.

18.01.2025 - MRNA Stock was up 6.6%

• Moderna's (MRNA) stock displayed a significant uptrend during the last trading session.
• Despite reservations voiced by analysts and a decrease in ratings, the company's Q4 financial performance surpassed expectations, including higher revenues, and restated its total revenue projections for 2025.
• The reduction in COVID vaccine sales was counterbalanced by the revenue outperformance. However, a loss was reported due to the downsizing of manufacturing operations, instigating uncertainty in the market.
• Emphasis seems to be placed on the favorable earnings and revenue outcomes rather than the drop in the COVID business, fueling the upward momentum in the stock price.

18.01.2025 - MRNA Stock was up 6.2%

• Moderna reported Q4 earnings and revenues that beat expectations, despite a decline in COVID vaccine sales. This positive financial performance likely contributed to the bullish movement in the stock.
• Despite scaling down manufacturing and facing growing pains, Moderna's ability to surpass revenue estimates showcased its resilience and potential for future growth.
• The downgrade by a top Wall Street analyst for another company, Hims & Hers Health, may have shifted investor focus towards Moderna, leading to increased buying activity and driving the stock price higher.
• Overall, Moderna's strong financial results and ongoing efforts to launch new products seem to have overshadowed any concerns about its COVID business decline, fueling investor optimism and driving the bullish movement in the stock.